Download PDF
J Pediatr Infect Dis 2016; 11(03): 106-112
DOI: 10.1055/s-0036-1597300
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Infections in Pediatric Kidney Transplant Recipients

Terry Dixon
1   Division of Pediatric Infectious Disease, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, United States
,
Katherine Twombley
2   Division of Pediatric Nephrology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, United States
› Author Affiliations
Further Information

Publication History

02 August 2016

11 September 2016

Publication Date:
12 December 2016 (online)

    Permissions and Reprints

Abstract

Infections after kidney transplant in children remain a significant problem. Infections can be viral (Epstein–Barr virus, cytomegalovirus, and BK virus), bacterial (urinary tract infections, wound infections, and pneumonia), or fungal (candidiasis and Pneumocystis jirovecii, formerly Pneumocystis carinii); all can have a significant negative impact on graft survival. Infections are typically defined as early (0–30 days posttransplant), intermediate (1–6 months posttransplant), or late (> 6 months posttransplant) depending on how far after transplant they occur. Here, we will review some of the common infections in children postkidney transplant.

Keywords

opportunistic infections - renal transplantation - viral infectious - allograft rejection
 

  • References

  • 1 Smith JM, Martz K, Blydt-Hansen TD. Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant 2013; 17 (02) 149-157
    CrossrefPubMedGoogle Scholar
  • 2 Matas AJ, Smith JM, Skeans MA. , et al. OPTN/SRTR 2013 annual data report: kidney. Am J Transplant 2015; 15 (Suppl. 02) 1-34
    PubMedGoogle Scholar
  • 3 Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63 (12) 1247-1297
    CrossrefPubMedGoogle Scholar
  • 4 Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26 (12) 1730-1744
    CrossrefPubMedGoogle Scholar
  • 5 Silva A, Rodig N, Passerotti CP. , et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 2010; 184 (04) 1462-1467
    CrossrefPubMedGoogle Scholar
  • 6 Feber J, Spatenka J, Seeman T. , et al. Urinary tract infections in pediatric renal transplant recipients--a two center risk factors study. Pediatr Transplant 2009; 13 (07) 881-886
    CrossrefPubMedGoogle Scholar
  • 7 Esezobor CI, Nourse P, Gajjar P. Urinary tract infection following kidney transplantation: frequency, risk factors and graft function. Pediatr Nephrol 2012; 27 (04) 651-657
    CrossrefPubMedGoogle Scholar
  • 8 John U, Kemper MJ. Urinary tract infections in children after renal transplantation. Pediatr Nephrol 2009; 24 (06) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 9 Weigel F, Lemke A, Tönshoff B. , et al. Febrile urinary tract infection after pediatric kidney transplantation: a multicenter, prospective observational study. Pediatr Nephrol 2016; 31 (06) 1021-1028
    CrossrefPubMedGoogle Scholar
  • 10 Robinson LG, Hilinski J, Graham F. , et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002; 6 (02) 111-118
    CrossrefPubMedGoogle Scholar
  • 11 Lapidus-Krol E, Shapiro R, Amir J. , et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010; 14 (06) 753-760
    CrossrefPubMedGoogle Scholar
  • 12 Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 2011; 91 (02) 245-250
    CrossrefPubMedGoogle Scholar
  • 13 Höcker B, Fickenscher H, Delecluse HJ. , et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 2013; 56 (01) 84-92
    CrossrefPubMedGoogle Scholar
  • 14 Suzuki T, Ikezumi Y, Okubo S. , et al. Epstein-Barr virus DNA load and seroconversion in pediatric renal transplantation with tacrolimus immunosuppression. Pediatr Transplant 2007; 11 (07) 749-754
    CrossrefPubMedGoogle Scholar
  • 15 Köpf S, Tönshoff B. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol 2004; 19 (04) 365-368
    CrossrefPubMedGoogle Scholar
  • 16 Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83 (11) 1423-1428
    CrossrefPubMedGoogle Scholar
  • 17 Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4 (12) 2109-2117
    CrossrefPubMedGoogle Scholar
  • 18 Jordan CL, Taber DJ, Kyle MO. , et al. Incidence, risk factors, and outcomes of opportunistic infections in pediatric renal transplant recipients. Pediatr Transplant 2016; 20 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 19 Li L, Chaudhuri A, Weintraub LA. , et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007; 11 (02) 187-195
    CrossrefPubMedGoogle Scholar
  • 20 Smith JM, Corey L, Bittner R. , et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21 (09) 1579-1586
    CrossrefPubMedGoogle Scholar
  • 21 Höcker B, Zencke S, Krupka K. , et al. Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)Ganciclovir. Transplantation 2016; 100 (04) 862-870
    CrossrefPubMedGoogle Scholar
  • 22 Kotton CN, Kumar D, Caliendo AM. , et al; Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96 (04) 333-360
    CrossrefPubMedGoogle Scholar
  • 23 Chapman JR. The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation 2010; 89 (06) 644-645
    CrossrefPubMedGoogle Scholar
  • 24 Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6 (02) 262-274
    CrossrefPubMedGoogle Scholar
  • 25 Smith JM, Dharnidharka VR. Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol 2015; 30 (05) 741-748
    CrossrefPubMedGoogle Scholar
  • 26 Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56 (01) 88-96
    CrossrefPubMedGoogle Scholar
  • 27 Walker RC, Paya CV, Marshall WF. , et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14 (02) 214-221
    PubMedGoogle Scholar
  • 28 Ho M, Miller G, Atchison RW. , et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152 (05) 876-886
    CrossrefPubMedGoogle Scholar
  • 29 Bingler MA, Feingold B, Miller SA. , et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008; 8 (02) 442-445
    CrossrefPubMedGoogle Scholar
  • 30 Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. Pediatr Transplant 2009; 13 (03) 319-323
    CrossrefPubMedGoogle Scholar
  • 31 Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. Pediatr Transplant 2010; 14 (04) 549-553
    CrossrefPubMedGoogle Scholar
  • 32 Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71 (08) 1065-1068
    CrossrefPubMedGoogle Scholar
  • 33 Rowe DT, Qu L, Reyes J. , et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35 (06) 1612-1615
    CrossrefPubMedGoogle Scholar
  • 34 Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003; 41 (11) 5245-5249
    CrossrefPubMedGoogle Scholar
  • 35 Hill CE, Harris SB, Culler EE, Zimring JC, Nolte FS, Caliendo AM. Performance characteristics of two real-time PCR assays for the quantification of Epstein-Barr virus DNA. Am J Clin Pathol 2006; 125 (05) 665-671
    CrossrefPubMedGoogle Scholar
  • 36 Twombley K, Pokala H, Ardura MI. , et al. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 2012; 16 (06) E201-E209
    CrossrefPubMedGoogle Scholar
  • 37 Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 03) S1-S155
    PubMedGoogle Scholar
  • 38 Allen U, Preiksaitis J. AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 04) S87-S96
    CrossrefPubMedGoogle Scholar
  • 39 Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1 (02) 103-108
    PubMedGoogle Scholar
  • 40 Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003; 50 (06) 1471-1491
    CrossrefPubMedGoogle Scholar
  • 41 Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3 (02) 79-87
    CrossrefPubMedGoogle Scholar
  • 42 Jongsma H, Bouts AH, Cornelissen EA, Beersma MF, Cransberg K. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience. Pediatr Transplant 2013; 17 (06) 510-517
    CrossrefPubMedGoogle Scholar
  • 43 Hashim F, Gregg JA, Dharnidharka VR. Efficacy of extended valganciclovir prophylaxis in preventing cytomegalovirus infection in pediatric kidney transplantation. Open Urol Nephrol J 2014; 7 , (2 suppl 2 M7) 152-157
    CrossrefPubMedGoogle Scholar
  • 44 Villeneuve D, Brothers A, Harvey E. , et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant 2013; 17 (01) 80-85
    CrossrefPubMedGoogle Scholar
  • 45 Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1 7712 1253-1257
    PubMedGoogle Scholar
  • 46 Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol 2006; 577: 19-45
    PubMedGoogle Scholar
  • 47 Ahsan N, Shah KV. Polyomaviruses and human diseases. Adv Exp Med Biol 2006; 577: 1-18
    PubMedGoogle Scholar
  • 48 Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. J Clin Microbiol 2009; 47 (08) 2388-2391
    CrossrefPubMedGoogle Scholar
  • 49 Vanchiere JA, Carillo B, Morrow AL, Jiang X, Ruiz-Palacios GM, Butel JS. Fecal polyomavirus excretion in infancy. J Pediatric Infect Dis Soc 2016; 5 (02) 210-213
    CrossrefPubMedGoogle Scholar
  • 50 Dharnidharka VR, Abdulnour HA, Araya CE. The BK virus in renal transplant recipients-review of pathogenesis, diagnosis, and treatment. Pediatr Nephrol 2011; 26 (10) 1763-1774
    CrossrefPubMedGoogle Scholar
  • 51 Zarauza Santoveña A, García Meseguer C, Martínez Mejía S. , et al. BK virus infection in pediatric renal transplantation. Transplant Proc 2015; 47 (01) 62-66
    CrossrefPubMedGoogle Scholar
  • 52 Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007; 2 (05) 1037-1042
    CrossrefPubMedGoogle Scholar
  • 53 Ginevri F, Azzi A, Hirsch HH. , et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7 (12) 2727-2735
    CrossrefPubMedGoogle Scholar
  • 54 Hirsch HH, Drachenberg CB, Steiger J, Ramos E. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006; 577: 160-173
    PubMedGoogle Scholar
  • 55 Liptak P, Kemeny E, Ivanyi B. Primer: histopathology of polyomavirus-associated nephropathy in renal allografts. Nat Clin Pract Nephrol 2006; 2 (11) 631-636
    CrossrefPubMedGoogle Scholar
  • 56 Drake KA, Najera L, Reed RC, Verghese PS. Unusual presentations of BK virus infections in pediatric renal transplant recipients. Pediatr Transplant 2013; 17 (01) E9-E15
    CrossrefPubMedGoogle Scholar
  • 57 Verghese PS, Schmeling DO, Knight JA, Matas AJ, Balfour Jr HH. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study. Transplantation 2015; 99 (03) 602-608
    CrossrefPubMedGoogle Scholar
  • 58 Hirsch HH, Brennan DC, Drachenberg CB. , et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79 (10) 1277-1286
    CrossrefPubMedGoogle Scholar
  • 59 Hirsch HH, Randhawa P. AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 04) S136-S146
    CrossrefPubMedGoogle Scholar
  • 60 Pham PT, Schaenman J, Pham PC. BK virus infection following kidney transplantation: an overview of risk factors, screening strategies, and therapeutic interventions. Curr Opin Organ Transplant 2014; 19 (04) 401-412
    CrossrefPubMedGoogle Scholar
  • 61 Jung YH, Moon KC, Ha JW. , et al. Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant 2013; 17 (02) E50-E54
    CrossrefPubMedGoogle Scholar
  • 62 Vu D, Shah T, Ansari J, Naraghi R, Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc 2015; 47 (02) 394-398
    CrossrefPubMedGoogle Scholar
  • 63 Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 2008; 12 (07) 790-795
    CrossrefPubMedGoogle Scholar
  • 64 Araya CE, Lew JF, Fennell III RS, Neiberger RE, Dharnidharka VR. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. Pediatr Transplant 2006; 10 (01) 32-37
    CrossrefPubMedGoogle Scholar
  • 65 Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr Transplant 2010; 14 (01) 145-150
    CrossrefPubMedGoogle Scholar
  • 66 Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61 (01) 35-41
    PubMedGoogle Scholar
  • 67 de Boer MG, de Fijter JW, Kroon FP. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2011; 49 (07) 673-680
    PubMedGoogle Scholar
  • 68 Sassi M, Ripamonti C, Mueller NJ. , et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54 (10) 1437-1444
    CrossrefPubMedGoogle Scholar
  • 69 Höcker B, Wendt C, Nahimana A, Tönshoff B, Hauser PM. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005; 11 (02) 330-332
    CrossrefPubMedGoogle Scholar
  • 70 Kasiske BL, Zeier MG, Chapman JR. , et al; Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77 (04) 299-311
    CrossrefPubMedGoogle Scholar
  • 71 Evans RA, Clifford TM, Tang S, Au T, Fugit AM. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation. Transpl Infect Dis 2015; 17 (06) 816-821
    CrossrefPubMedGoogle Scholar